patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_995866 | REC_0013801 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 19.1 | 69 | female | 1 | 11 | 5.2 | 2 | osimertinib 80 mg daily | 14.5 | true | MSI-H | 2026-03-15T05:36:00.530777+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_545951 | REC_0013802 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 9.8 | 79 | female | 2 | 8 | 4.9 | 1 | osimertinib 80 mg daily | 15.2 | false | MSS | 2026-03-15T05:36:00.531070+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_811464 | REC_0013803 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 13.9 | 57 | female | 1 | 21 | 2.7 | 4 | sotorasib 960 mg daily | 11.3 | false | MSS | 2026-03-15T05:36:00.531360+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_185612 | REC_0013804 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 14.1 | 60 | female | 1 | 5 | 7 | 4 | sotorasib 960 mg daily | 12.8 | true | MSS | 2026-03-15T05:36:00.531695+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_250407 | REC_0013805 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 23 | 6.4 | 68 | female | 1 | 62 | 6.1 | 0 | pembrolizumab 200 mg q3w | 31.4 | true | MSS | 2026-03-15T05:36:00.532069+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_266262 | REC_0013806 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 13.7 | 71 | female | 3 | 36 | 6.2 | 5 | osimertinib 80 mg daily | 10.1 | true | MSS | 2026-03-15T05:36:00.532521+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_976428 | REC_0013807 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 19 | 8.2 | 69 | female | 1 | 15 | 5.6 | 0 | alectinib 600 mg BID | 39.2 | true | MSS | 2026-03-15T05:36:00.533039+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_316033 | REC_0013808 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 18 | 9.7 | 65 | male | 0 | 12 | 6.5 | 1 | osimertinib 80 mg daily | 21.1 | true | MSS | 2026-03-15T05:36:00.533418+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_819494 | REC_0013809 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 11.4 | 70 | female | 0 | 20 | 5.7 | 4 | sotorasib 960 mg daily | 10.5 | true | MSS | 2026-03-15T05:36:00.533775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_373167 | REC_0013810 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 24 | 5.4 | 62 | male | 0 | 20 | 8 | 2 | pembrolizumab 200 mg q3w | 17.5 | false | MSS | 2026-03-15T05:36:00.534122+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_563949 | REC_0013811 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 28 | 4.2 | 78 | female | 1 | 21 | 4.8 | 7 | pembrolizumab 200 mg q3w | 15.8 | false | MSS | 2026-03-15T05:36:00.534451+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_937228 | REC_0013812 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 15 | 4.8 | 59 | male | 1 | 42 | 4 | 4 | pembrolizumab 200 mg q3w | 14.2 | false | MSS | 2026-03-15T05:36:00.534759+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_696070 | REC_0013813 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 11 | 71 | female | 2 | 17 | 4.6 | 2 | alectinib 600 mg BID | 14.4 | true | MSS | 2026-03-15T05:36:00.535068+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_296723 | REC_0013814 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 11.5 | 72 | female | 1 | 9 | 5.1 | 6 | osimertinib 80 mg daily | 14.3 | false | MSS | 2026-03-15T05:36:00.535369+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_275682 | REC_0013815 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 11.3 | 72 | male | 2 | 15 | 7 | 4 | entrectinib 600 mg daily | 8 | false | MSS | 2026-03-15T05:36:00.535689+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_896737 | REC_0013816 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 14.5 | 66 | female | 1 | 10 | 4.6 | 5 | alectinib 600 mg BID | 14.2 | true | MSS | 2026-03-15T05:36:00.535991+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_421182 | REC_0013817 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 7.3 | 68 | female | 0 | 18 | 7 | 1 | alectinib 600 mg BID | 4 | true | MSS | 2026-03-15T05:36:00.536356+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_797547 | REC_0013818 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 16.2 | 67 | male | 0 | 13 | 8.1 | 8 | entrectinib 600 mg daily | 12.2 | false | MSI-H | 2026-03-15T05:36:00.536670+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_224227 | REC_0013819 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 13.4 | 69 | female | 0 | 11 | 6 | 1 | alectinib 600 mg BID | 21.4 | false | MSI-H | 2026-03-15T05:36:00.536982+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_485697 | REC_0013820 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 5.2 | 74 | female | 1 | 8 | 4.7 | 2 | osimertinib 80 mg daily | 18.7 | true | MSS | 2026-03-15T05:36:00.537458+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_798202 | REC_0013821 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 9.5 | 73 | female | 2 | 21 | 5.3 | 1 | entrectinib 600 mg daily | 13.1 | false | MSS | 2026-03-15T05:36:00.537782+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_117785 | REC_0013822 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 19 | 16.6 | 57 | male | 1 | 6 | 6.6 | 0 | osimertinib 80 mg daily | 17.9 | false | MSS | 2026-03-15T05:36:00.538664+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_221183 | REC_0013823 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 9.8 | 66 | female | 1 | 7 | 4.1 | 4 | sotorasib 960 mg daily | 10.4 | true | MSS | 2026-03-15T05:36:00.539102+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_622231 | REC_0013824 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 14.1 | 75 | female | 2 | 18 | 6.4 | 5 | sotorasib 960 mg daily | 16.6 | true | MSI-H | 2026-03-15T05:36:00.539465+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_844751 | REC_0013825 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 28 | 9.5 | 66 | male | 1 | 14 | 5.3 | 5 | pembrolizumab 200 mg q3w | 10.1 | false | MSS | 2026-03-15T05:36:00.539775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_904533 | REC_0013826 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 11.4 | 64 | male | 1 | 0 | 7.8 | 4 | osimertinib 80 mg daily | 9.8 | true | MSS | 2026-03-15T05:36:00.540128+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_145080 | REC_0013827 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.5 | 58 | male | 1 | 22 | 5.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 16.3 | true | MSS | 2026-03-15T05:36:00.540604+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344337 | REC_0013828 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 10.6 | 72 | male | 1 | 17 | 5.8 | 3 | osimertinib 80 mg daily | 9.4 | false | MSS | 2026-03-15T05:36:00.540978+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_990985 | REC_0013829 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 7.3 | 58 | female | 0 | 17 | 5.5 | 2 | osimertinib 80 mg daily | 17.3 | true | MSS | 2026-03-15T05:36:00.541282+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_580057 | REC_0013830 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 11.6 | 61 | male | 0 | 18 | 4.9 | 2 | pembrolizumab 200 mg q3w | 4.6 | true | MSS | 2026-03-15T05:36:00.542653+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_541078 | REC_0013831 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 15.4 | 66 | male | 1 | 1 | 5.5 | 2 | entrectinib 600 mg daily | 12.5 | false | MSI-H | 2026-03-15T05:36:00.543067+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_424680 | REC_0013832 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 7.4 | 66 | female | 0 | 13 | 4.2 | 2 | osimertinib 80 mg daily | 24.8 | false | MSS | 2026-03-15T05:36:00.543381+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_882749 | REC_0013833 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 10.3 | 56 | male | 1 | 5 | 6.5 | 8 | osimertinib 80 mg daily | 4.9 | true | MSS | 2026-03-15T05:36:00.543854+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_859889 | REC_0013834 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 6.5 | 64 | female | 0 | 12 | 5.9 | 1 | osimertinib 80 mg daily | 17.9 | true | MSS | 2026-03-15T05:36:00.544263+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_839717 | REC_0013835 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 17 | 15.8 | 62 | female | 0 | 8 | 4.8 | 0 | osimertinib 80 mg daily | 40.9 | false | MSS | 2026-03-15T05:36:00.544612+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_277435 | REC_0013836 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 10.2 | 81 | male | 1 | 18 | 6.3 | 6 | sotorasib 960 mg daily | 7.7 | false | MSI-H | 2026-03-15T05:36:00.545046+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_998516 | REC_0013837 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 15 | 8.7 | 62 | male | 0 | 17 | 5.1 | 3 | pembrolizumab 200 mg q3w | 12 | false | MSS | 2026-03-15T05:36:00.545706+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_239039 | REC_0013838 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 7.8 | 69 | female | 0 | 7 | 5.8 | 2 | pembrolizumab 200 mg q3w | 18.7 | true | MSS | 2026-03-15T05:36:00.546060+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_175049 | REC_0013839 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 3.7 | 76 | female | 2 | 7 | 3.6 | 7 | osimertinib 80 mg daily | 10.1 | false | MSS | 2026-03-15T05:36:00.546372+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_486812 | REC_0013840 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 32 | 14.9 | 63 | male | 0 | 20 | 6.4 | 1 | osimertinib 80 mg daily | 12.4 | true | MSI-H | 2026-03-15T05:36:00.546678+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690870 | REC_0013841 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 15.7 | 56 | male | 0 | 6 | 4.7 | 1 | entrectinib 600 mg daily | 7.5 | false | MSS | 2026-03-15T05:36:00.547083+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_390440 | REC_0013842 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 6.2 | 60 | female | 0 | 39 | 5.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 8.3 | false | MSS | 2026-03-15T05:36:00.547444+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_360103 | REC_0013843 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 17 | 7.3 | 62 | male | 1 | 20 | 5.6 | 2 | osimertinib 80 mg daily | 11.3 | true | MSS | 2026-03-15T05:36:00.547766+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_797447 | REC_0013844 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 8.1 | 54 | male | 0 | 23 | 4.8 | 1 | alectinib 600 mg BID | 10.4 | false | MSS | 2026-03-15T05:36:00.548128+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_643636 | REC_0013845 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 21 | 11.6 | 75 | male | 1 | 24 | 6.7 | 0 | osimertinib 80 mg daily | 39.1 | true | MSS | 2026-03-15T05:36:00.550992+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322724 | REC_0013846 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 13.8 | 70 | female | 1 | 15 | 3.1 | 4 | entrectinib 600 mg daily | 9.8 | false | MSS | 2026-03-15T05:36:00.551645+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_846523 | REC_0013847 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 13.7 | 63 | male | 1 | 34 | 7.2 | 5 | entrectinib 600 mg daily | 11.2 | false | MSI-H | 2026-03-15T05:36:00.552034+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_261905 | REC_0013848 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 9.9 | 63 | female | 0 | 9 | 6 | 7 | osimertinib 80 mg daily | 11.3 | false | MSS | 2026-03-15T05:36:00.552443+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_597049 | REC_0013849 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 14.9 | 70 | male | 2 | 14 | 4.7 | 10 | osimertinib 80 mg daily | 5.6 | false | MSI-H | 2026-03-15T05:36:00.552757+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_203097 | REC_0013850 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 10.4 | 64 | female | 0 | 14 | 4.1 | 7 | osimertinib 80 mg daily | 7.6 | true | MSI-H | 2026-03-15T05:36:00.553065+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_701473 | REC_0013851 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 9.7 | 62 | female | 1 | 23 | 5.2 | 5 | osimertinib 80 mg daily | 15.2 | false | MSS | 2026-03-15T05:36:00.553358+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_268526 | REC_0013852 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 10.7 | 67 | female | 1 | 7 | 4.8 | 6 | entrectinib 600 mg daily | 16 | false | MSI-H | 2026-03-15T05:36:00.553663+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_333893 | REC_0013853 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 10.5 | 71 | female | 2 | 12 | 7.7 | 2 | osimertinib 80 mg daily | 8.8 | true | MSS | 2026-03-15T05:36:00.553961+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_729623 | REC_0013854 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 36 | 14.7 | 54 | male | 0 | 15 | 6.5 | 1 | sotorasib 960 mg daily | 20.7 | false | MSI-H | 2026-03-15T05:36:00.554269+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_408093 | REC_0013855 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 17.4 | 76 | female | 2 | 13 | 4.4 | 1 | osimertinib 80 mg daily | 16.5 | true | MSS | 2026-03-15T05:36:00.554602+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_111348 | REC_0013856 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 35 | 3.9 | 66 | female | 0 | 33 | 3.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 30.5 | false | MSS | 2026-03-15T05:36:00.554959+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_760167 | REC_0013857 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 11.5 | 80 | female | 1 | 11 | 5.6 | 6 | alectinib 600 mg BID | 7.7 | true | MSS | 2026-03-15T05:36:00.555327+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_255574 | REC_0013858 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 34 | 8.8 | 75 | male | 0 | 20 | 2.7 | 0 | osimertinib 80 mg daily | 51.3 | false | MSS | 2026-03-15T05:36:00.555685+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_351128 | REC_0013859 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 27 | 15.1 | 65 | male | 1 | 8 | 6.1 | 2 | pembrolizumab 200 mg q3w | 13.4 | true | MSI-H | 2026-03-15T05:36:00.556281+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_255207 | REC_0013860 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 1.5 | 73 | female | 2 | 55 | 4.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 16.4 | true | MSS | 2026-03-15T05:36:00.556704+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_290566 | REC_0013861 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 6.1 | 69 | female | 0 | 9 | 6.5 | 8 | alectinib 600 mg BID | 17.6 | false | MSS | 2026-03-15T05:36:00.557095+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_880266 | REC_0013862 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 17 | 60 | female | 0 | 21 | 4.7 | 3 | sotorasib 960 mg daily | 8 | false | MSS | 2026-03-15T05:36:00.557465+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_852228 | REC_0013863 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 19 | 5.2 | 62 | male | 1 | 11 | 8.7 | 2 | sotorasib 960 mg daily | 25.7 | true | MSS | 2026-03-15T05:36:00.557842+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_415097 | REC_0013864 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 3.9 | 67 | female | 0 | 87 | 3.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 12.9 | true | MSS | 2026-03-15T05:36:00.558321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_578128 | REC_0013865 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 28 | 7.5 | 64 | male | 0 | 25 | 4.7 | 1 | pembrolizumab 200 mg q3w | 7.7 | true | MSS | 2026-03-15T05:36:00.558735+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_824660 | REC_0013866 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 16.3 | 69 | female | 0 | 14 | 6.8 | 1 | alectinib 600 mg BID | 16.4 | false | MSS | 2026-03-15T05:36:00.559112+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_153270 | REC_0013867 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 10.4 | 66 | female | 1 | 11 | 6.2 | 5 | pembrolizumab 200 mg q3w | 6.7 | true | MSI-H | 2026-03-15T05:36:00.559492+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_128082 | REC_0013868 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 15.1 | 65 | male | 0 | 10 | 3.8 | 5 | sotorasib 960 mg daily | 11.4 | false | MSI-H | 2026-03-15T05:36:00.559841+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826164 | REC_0013869 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 5.3 | 65 | female | 1 | 23 | 5.2 | 4 | entrectinib 600 mg daily | 13.4 | false | MSS | 2026-03-15T05:36:00.560287+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_813801 | REC_0013870 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 13.3 | 70 | female | 1 | 12 | 5.8 | 5 | entrectinib 600 mg daily | 10.9 | true | MSS | 2026-03-15T05:36:00.560765+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_323006 | REC_0013871 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 10.4 | 59 | male | 0 | 17 | 3.6 | 5 | sotorasib 960 mg daily | 16.9 | true | MSS | 2026-03-15T05:36:00.561187+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_608685 | REC_0013872 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 9.2 | 63 | female | 1 | 18 | 4.4 | 2 | sotorasib 960 mg daily | 13.8 | false | MSS | 2026-03-15T05:36:00.561811+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_947309 | REC_0013873 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 21.8 | 62 | male | 0 | 17 | 5.2 | 7 | alectinib 600 mg BID | 10.3 | false | MSI-H | 2026-03-15T05:36:00.562244+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_791674 | REC_0013874 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 8 | 63 | male | 1 | 53 | 5.5 | 3 | carboplatin + paclitaxel + pembrolizumab | 18 | true | MSS | 2026-03-15T05:36:00.562633+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_467113 | REC_0013875 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 16.5 | 73 | female | 2 | 16 | 6.1 | 2 | osimertinib 80 mg daily | 11.5 | false | MSS | 2026-03-15T05:36:00.563016+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_530056 | REC_0013876 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 20 | 6.4 | 63 | female | 1 | 42 | 4.6 | 0 | carboplatin + paclitaxel + pembrolizumab | 38.7 | false | MSS | 2026-03-15T05:36:00.563395+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_793325 | REC_0013877 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 6.6 | 59 | male | 1 | 44 | 6.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 6.1 | false | MSS | 2026-03-15T05:36:00.563872+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_543272 | REC_0013878 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 19 | 4.8 | 63 | male | 0 | 55 | 5.9 | 9 | pembrolizumab 200 mg q3w | 10.7 | false | MSS | 2026-03-15T05:36:00.564492+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_501996 | REC_0013879 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 11.9 | 64 | male | 1 | 18 | 4.6 | 7 | osimertinib 80 mg daily | 10.1 | false | MSS | 2026-03-15T05:36:00.564971+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_215801 | REC_0013880 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 13.2 | 70 | female | 2 | 21 | 6 | 4 | entrectinib 600 mg daily | 14.9 | true | MSS | 2026-03-15T05:36:00.565397+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_268248 | REC_0013881 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 11.6 | 59 | female | 0 | 13 | 2.7 | 1 | entrectinib 600 mg daily | 19.8 | false | MSI-H | 2026-03-15T05:36:00.565803+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_414506 | REC_0013882 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 17.9 | 60 | female | 1 | 13 | 4.4 | 8 | alectinib 600 mg BID | 5.8 | true | MSI-H | 2026-03-15T05:36:00.566197+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_454280 | REC_0013883 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 8 | 75 | male | 2 | 16 | 7.3 | 6 | pembrolizumab 200 mg q3w | 11 | true | MSS | 2026-03-15T05:36:00.566596+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_903510 | REC_0013884 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 13 | 6.7 | 82 | female | 1 | 14 | 5.3 | 6 | pembrolizumab 200 mg q3w | 7 | true | MSS | 2026-03-15T05:36:00.566983+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_915154 | REC_0013885 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 22 | 11.7 | 76 | male | 1 | 6 | 5.1 | 2 | pembrolizumab 200 mg q3w | 16.2 | false | MSS | 2026-03-15T05:36:00.567537+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_653162 | REC_0013886 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 12.2 | 63 | male | 1 | 7 | 6.6 | 1 | osimertinib 80 mg daily | 32.7 | true | MSI-H | 2026-03-15T05:36:00.567934+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_863854 | REC_0013887 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 9.4 | 67 | female | 1 | 13 | 6.9 | 2 | osimertinib 80 mg daily | 16.7 | false | MSS | 2026-03-15T05:36:00.568353+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_172952 | REC_0013888 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 17 | 8.9 | 58 | male | 1 | 16 | 6.7 | 1 | entrectinib 600 mg daily | 21.9 | true | MSS | 2026-03-15T05:36:00.568675+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_936872 | REC_0013889 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 10.7 | 62 | male | 1 | 17 | 7.8 | 2 | entrectinib 600 mg daily | 20.2 | false | MSS | 2026-03-15T05:36:00.568967+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_956508 | REC_0013890 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 16.3 | 56 | female | 1 | 19 | 5.9 | 7 | alectinib 600 mg BID | 17.6 | true | MSI-H | 2026-03-15T05:36:00.569259+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_347601 | REC_0013891 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 1.5 | 63 | female | 0 | 9 | 5.5 | 4 | sotorasib 960 mg daily | 10.7 | false | MSS | 2026-03-15T05:36:00.569548+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_129674 | REC_0013892 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 14.1 | 70 | female | 2 | 10 | 4.7 | 6 | osimertinib 80 mg daily | 10.6 | true | MSS | 2026-03-15T05:36:00.569833+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_748190 | REC_0013893 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 15.9 | 67 | female | 0 | 15 | 5.9 | 6 | alectinib 600 mg BID | 16.3 | false | MSS | 2026-03-15T05:36:00.570145+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_315370 | REC_0013894 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 1.5 | 74 | male | 2 | 8 | 2.1 | 4 | entrectinib 600 mg daily | 8.1 | false | MSS | 2026-03-15T05:36:00.570448+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_983356 | REC_0013895 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 11.9 | 63 | female | 0 | 12 | 5.8 | 4 | entrectinib 600 mg daily | 12.8 | false | MSS | 2026-03-15T05:36:00.570754+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_921330 | REC_0013896 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 14.9 | 61 | male | 0 | 13 | 5.7 | 2 | entrectinib 600 mg daily | 4.5 | true | MSI-H | 2026-03-15T05:36:00.571055+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_443108 | REC_0013897 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 10 | 60 | male | 0 | 24 | 6.2 | 4 | osimertinib 80 mg daily | 18.2 | true | MSI-H | 2026-03-15T05:36:00.571347+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_634836 | REC_0013898 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 12.4 | 78 | female | 3 | 4 | 7.2 | 7 | alectinib 600 mg BID | 16.2 | true | MSS | 2026-03-15T05:36:00.571766+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_860214 | REC_0013899 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 17.5 | 54 | female | 0 | 12 | 6.3 | 5 | osimertinib 80 mg daily | 8.3 | false | MSI-H | 2026-03-15T05:36:00.572163+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_501025 | REC_0013900 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 6.1 | 75 | female | 1 | 20 | 7.1 | 4 | alectinib 600 mg BID | 8.2 | false | MSS | 2026-03-15T05:36:00.572497+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.